NG101m / NeuGATE Pharma - LARVOL DELTA

NG101m Adjuvant Therapy in Glioblastoma Patients (clinicaltrials.gov) - P1/2 | N=52 | Not yet recruiting | Sponsor: NeuGATE Theranostics | Phase classification: P2 ➔ P1/2 | Trial completion date: Dec 2027 ➔ Dec 2030 | Trial primary completion date: Jul 2027 ➔ Jul 2030

Phase classification • Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

NG101m Adjuvant Therapy in Glioblastoma Patients (clinicaltrials.gov) - P2 | N=52 | Not yet recruiting | Sponsor: NeuGATE Theranostics | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

NG101m Adjuvant Therapy in Glioblastoma Patients (clinicaltrials.gov) - P2 | N=52 | Not yet recruiting | Sponsor: NeuGATE Theranostics | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

NG101m Adjuvant Therapy in Glioblastoma Patients (clinicaltrials.gov) - P2; N=52; Not yet recruiting; Sponsor: NeuGATE Theranostics; Trial completion date: Jun 2026 ➔ Dec 2025; Initiation date: Jun 2020 ➔ Jul 2021; Trial primary completion date: Jun 2024 ➔ Jul 2025

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

NG101m Adjuvant Therapy in Glioblastoma Patients (clinicaltrials.gov) - P2; N=52; Not yet recruiting; Sponsor: NeuGATE Theranostics

Clinical • New P2 trial